About six in every thousand gallbladders removed for stones contain cancer. A written pathway that sends every specimen to the pathologist, refers every T1b or deeper cancer to a liver surgeon within two weeks and books the second operation within eight would turn a lottery into a system.
Incidental cancer is 0.6 percent of cholecystectomies (Pyo 2020). In the Netherlands only 24 percent of eligible patients were re-resected (2020); in the UK CAPBIL cohort 67.7 percent had liver resection (2026), with the reasons for the rest unknown. Observational data favour re-resection at four to eight weeks (Ethun 2017) though a 2026 individual patient data meta-analysis found timing did not change survival, so the pathway should prioritise completion over speed. Selective histology policies risk missing cancers (Khan 2021 systematic review). A national pathway with audit, the model the NHS uses for other two-week-wait cancers, needs no new drug and could be measured through existing registries.
This is the UK baseline for the incidental cancer pathway: a re-resection rate well above the Dutch registry's 24 percent, with the same selection caveat. The abstract leaves out the histology, referral and timing detail; the full paper holds it.
It softens the Ethun four-to-eight-week rule: timing within the range that services can deliver probably matters less than completing the operation at all and doing it with the liver bed and nodes cleared.
Six per thousand is the number behind the debate on routine versus selective histology of gallbladder specimens: applied to a national cholecystectomy volume it predicts a few hundred unsuspected cancers a year in a country the size of England.
A whole-country picture of the gap between guideline and practice: three quarters of eligible patients never reached the second operation. The survival difference is confounded by selection but the residual disease rate is not.
The origin of the widely quoted four-to-eight-week window for re-resection. A 2026 individual patient data meta-analysis found no survival difference by timing, so the window is a reasonable planning target rather than a proven rule.
Shares Incidental gallbladder cancer (found after cholecystectomy), Radical (extended) cholecystectomy, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Gallbladder cancer and the tag gallbladder-evidence.
Shares Incidental gallbladder cancer (found after cholecystectomy), Radical (extended) cholecystectomy, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Gallbladder cancer and the tag gallbladder-evidence.
Shares Incidental gallbladder cancer (found after cholecystectomy), Radical (extended) cholecystectomy, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Gallbladder cancer and the tag gallbladder-evidence.
Shares OPT-IN (EA2197), Incidental gallbladder cancer (found after cholecystectomy), Radical (extended) cholecystectomy, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials and the tag gallbladder-evidence.
Shares Management of incidental gallbladder cancer in the nationwide CAPBIL study, Radical (extended) cholecystectomy, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Gallbladder cancer and the tag gallbladder-evidence.
Shares Incidental gallbladder cancer (found after cholecystectomy), Radical (extended) cholecystectomy, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Gallbladder cancer and the tag gallbladder-evidence.
Shares Incidental gallbladder cancer (found after cholecystectomy), Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Gallbladder cancer and the tag gallbladder-evidence.
Shares OPT-IN (EA2197), Incidental gallbladder cancer (found after cholecystectomy), Gallbladder cancer and the tag gallbladder-evidence.